OBJECTIVE -To determine the extent of ␤-cell function in youth with diabetes and GAD65 and/or IA2 autoantibodies.
I
mmune-mediated ␤-cell destruction, marked by the presence of diabetes autoantibodies, occurs before and continues after the clinical diagnosis of type 1 diabetes. This model has served as the foundation of pathophysiological studies of the disease process and clinical studies designed to identify future risk for diabetes and to modify clinical course. The resultant perception is that most individuals with type 1 diabetes will have complete destruction of ␤-cells within a few years after diagnosis without a targeted intervention to sustain ␤-cell function.
Despite frequent use of this model in research and patient care, it represents only part of the picture. Data from placebo-controlled populations in clinical intervention trials suggest that some individuals with type 1 diabetes will have persistent ␤-cell function years after diagnosis (1, 2) . The screening phase of the Diabetes Control and Complications Trial (DCCT) demonstrated that 48% of adults had significant C-peptide levels within 5 years of diagnosis, and 8% had significant Cpeptide 5-15 years after diagnosis (3) . Another study reported similar findings in 15% of individuals with measurable Cpeptide levels 8 -15 years after diagnosis (4) . Multiple studies have reported that the loss of ␤-cell function after diagnosis is related to age of onset as well as to factors linked to autoimmunity such as autoantibodies (5) (6) (7) (8) (9) (10) (11) . Nonetheless, there is a common belief that persistence of ␤-cell function is rare in young children with type 1 diabetes.
The SEARCH for Diabetes in Youth (SEARCH) study, designed to determine the prevalence, incidence, and characteristics of diabetes in U.S. youth, provides an opportunity to examine the frequency of residual ␤-cell function in a population-based sample of GAD65 ϩ or IA2 ϩ youth with diabetes.
RESEARCH DESIGN AND METHODS -Data for this analysis
derive from the SEARCH study as described previously (12) . SEARCH is a population-based study conducted at six centers in the U.S., including existing (prevalent) and newly diagnosed (incident) cases of diabetes in youth aged Ͻ20 years. Participants were asked to complete an initial survey and then were invited to an in-person study visit. After informed consent was provided, a brief examination was performed and blood samples were obtained.
Study population
Youth with prevalent cases in 2001 and incident cases in 2002-2005 who partic-
ipated in the in-person visit and had fasting C-peptide measured were eligible for this study (n ϭ 4,529 C-peptide categories DCCT. Post hoc analysis of DCCT data demonstrated that those with preserved C-peptide, defined as stimulated Cpeptide, value Ͼ0.6 ng/ml, had superior clinical outcomes, including less hypoglycemia and retinopathy, than those with lower C-peptide (13) . Re-analysis of these data indicated that the corresponding fasting C-peptide was 0.23 ng/ml (J. Lachin, P.F. McGee, personal communication). Fasting C-peptide values Ն0.23 ng/ml are therefore considered clinically significant. Healthy adolescents. The 5th and 50th percentiles of fasting C-peptide in healthy adolescents, aged 12-19 years, who participated in the National Health and Nutrition Survey 1999 -2002 (NHANES), were, respectively, 1.0 and 1.9 ng/ml (14).
Statistics SAS for Windows (version 9.1; SAS Institute, Cary, NC) was used for analysis. 2 or t tests were used to evaluate relationships between preserved ␤-cell function status and characteristics of interest. Two sets of regression models were run. The first included logistic regression models examining associations between variables of interest and preserved ␤-cell function status, stratified by duration of diabetes (Ͻ1, 1-2, and Ͼ2 years). Next, among participants with preserved C-peptide levels based on the DCCT cutoff, multiple linear regression models were used to identify variables significantly associated with fasting C-peptide levels. All logistic and linear regression models included the following covariates: age at diagnosis, sex, race/ethnicity, BMI Z score at time of the visit, A1C, number of autoantibodies present, fasting plasma glucose, and HLA genotype. In addition, linear models were adjusted for duration of disease.
RESULTS -The average age at diagnosis was 9.0 years: in 16% (n ϭ 434) of the individuals diabetes was diagnosed when they were Ͻ5 years of age, 38% (n ϭ 1,057) were between ages 5 and 10, 37% (n ϭ 1,028) were between ages 11 and 15, and 10% (n ϭ 270) were between 15 and 19 years of age at diagnosis. Average duration of diabetes was 3 years, with 33% (n ϭ 925) having duration of Ͻ1 year, 24% (n ϭ 661) having duration of 1-2 years, and 43% (n ϭ 1,202) having duration of Նyears.
Among individuals with duration of diabetes of Ͻ1 year, 82.9% had a fasting C-peptide level Ն0.23 ng/ml, 31.2% had fasting C-peptide at or above the 5th percentile of the NHANES population and 7.2% had fasting C-peptide at or above the NHANES 50th percentile level. As expected, the proportion of individuals with preserved C-peptide diminished with increasing disease duration. This finding is illustrated in Fig. 1 , which shows the proportion with preserved C-peptide in quarterly intervals from time from diagnosis. Among those with duration of Ն5 years, 10.7% had preserved C-peptide at the DCCT cut point, 1.0% at NHANES 5th percentile, and 0% at NHANES 50th percentile.
We then explored various characteristics of participants with and without preserved fasting C-peptide (Table 1 ). In the unadjusted analysis, the proportion of non-Hispanic whites who had preserved fasting C-peptide was smaller than that of other race/ethnicities. More individuals with preserved C-peptide had two antibodies and a significantly higher percentage of HLA DR15. In addition, those with preserved fasting C-peptide were older at diagnosis, had a shorter duration of diabetes, and had a lower A1C at the time of the study visit. Those with C-peptide above the NHANES 5th percentile also had a higher BMI Z score than those with C-peptide below this level. Figure 2 presents the results of the multiple logistic regression models with the dichotomous outcome of preserved fasting C-peptide status based on the DCCT definition stratified by diabetes duration. Variables found to be independently associated with preserved ␤-cell function in all the models included older age at diagnosis and lower A1C at time of study visit. Race/ ethnicity other than non-Hispanic white was also significant for those participants with diabetes duration of 1-2 years and Ն2 years; higher current BMI Z score was also significant only for those participants with duration of 1-2 years (Fig. 2) .
Among those with preserved fasting C-peptide (DCCT definition), older age at diagnosis, higher current BMI Z score, race/ethnicity other than non-Hispanic white, female sex, lower A1C, and shorter duration of diabetes were independently related to higher fasting C-peptide levels. The association of age at diagnosis and diabetes duration with fasting C-peptide is illustrated in Fig. 3 , demonstrating that lower fasting C-peptide is seen in participants with diagnosis of diabetes at a younger age and those with longer duration of disease. The relationship between weight categories at the time of the study visit and prevalence of preserved ␤-cell function at various times from diagnosis is shown in Fig. 4 . Although a greater percentage of obese/overweight compared ␤-Cell function in youth with ab؉ diabetes with underweight subjects had preserved function, the association was significant (P Ͻ 0.0001) only in those with duration of diabetes of Ͻ2 years (P ϭ 0.48, 0.41, and 0.58 for 2-4, 4 -6, and Ͼ6 years from diagnosis, respectively).
CONCLUSIONS -In this study we found that approximately four of five youth with antibody-positive diabetes Data are n (%) or mean (range). For the column "Entire cohort," percentages total to 100 vertically within each variable (sex, race/ethnicity, HLA, and autoantibody number). For the remaining columns, the percentages total to 100 horizontally between preserved and not preserved for each definition. All continuous variables were different between those with preserved and not preserved C-peptide (t test; P Ͻ 0.05), except age at visit and BMI Z score for DCCT cutoff. Race/ethnicity, number of autoantibodies, and HLA DR showed a significant association with preserved status ( have clinically significant amounts of residual ␤-cell function within the 1st year after diagnosis. In adjusted regression analyses of individuals within 1 year of diagnosis only age at diagnosis and A1C were identified as significant variables in whether or not C-peptide was preserved. In addition, race/ethnicity was important in those further from diagnosis. Although it is known that ␤-cell function continues to decline after diabetes diagnosis, our data also indicate that as many as 1 of 10 
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youth have preserved ␤-cell function even 5 years after diagnosis. Despite evidence to the contrary, the belief persists that youth with type 1 diabetes have little insulin secretion at diagnosis and that insulin secretion rapidly disappears after diagnosis. Classification schemes define type 1 diabetes as a state of absolute insulin deficiency and type 2 diabetes as a state of insulin resistance combined with inadequate insulin secretion (15) . Thus, health care providers have used C-peptide measurements clinically to establish type of diabetes and to select therapies. Although this analysis does not address the question of whether there is a C-peptide cut point value that could distinguish different types of diabetes, the data demonstrate that many youth with antibody-positive diabetes have Cpeptide levels within the range of those of the normal population. Specifically, within 1 year of diagnosis, almost onethird of subjects had C-peptide values that exceeded the 5th percentile and ϳ1 in 14 (7%) exceeded the 50th percentile for healthy adolescents.
Most researchers (3,13,16 -20) , but not all (21) , documented that even a small amount of residual ␤-cell function is of clinical significance. Using a level of Cpeptide associated with clinical significance in the DCCT, we found that 82.9% of participants with diabetes duration of Ͻ1 year exceed this threshold. The frequency of clinically significant ␤-cell function is lower among youth with longer duration of disease (53.3% for duration of 1-2 years and 18.6% for 4 -5 years). Because the DCCT cut point has been suggested as an end point for clinical trials designed to preserve ␤-cell function, we suggest caution in interpreting data from nonrandomized trials or shortterm pilot studies because our data show that endogenous C-peptide is present years after diagnosis in a substantial portion of children.
The data in the present study are similar to those reported by the DCCT, in which 33% of the 466 adolescents tested Ͻ5 years from diagnosis had residual ␤-cell function. Because the DCCT population only included individuals aged Ͼ13 years, many pediatricians felt that preservation of C-peptide was unlikely in younger children. Among SEARCH participants, we found a profound impact of advancing age at diagnosis on preservation of C-peptide production. The association was linear throughout the complete range of age of diagnosis (from 1 to 20 years), suggesting that insulin resistance associated with puberty does not account for this finding. Others have demonstrated an effect of age on Cpeptide in individuals at risk for type 1 diabetes (22) .
Several reasons have been suggested for preserved ␤-cell function. First, increased awareness of the symptoms of type 1 diabetes and improved screening and diagnostic tools may have resulted in diagnosis at an earlier point in the autoimmune destruction of the ␤-cells. Thus, the individuals may have more ␤-cell reserve at diagnosis. Second, aggressive treatment at diagnosis, with rapid and tight control of hyperglycemia, may result in improved ␤-cell function (23) . Third, increased insulin resistance associated with the epidemic of obesity may have created a greater strain on the declining ␤-cell function resulting in diagnosis at a time when the individuals have more ␤-cell function than individuals in the past (24) . Consistent with this concept, among those with preserved ␤-cell function, BMI Z score was an important variable in determining the fasting C-peptide level. However, the impact of BMI on whether or not C-peptide was preserved was less clear. As evident in Fig. 4 , even many years from diagnosis, about 10% of normal-weight individuals had preserved function, suggesting that other, as yet, uncharacterized factors contribute to heterogeneity in disease progression.
This study also emphasizes the relationship between A1C and C-peptide but provides no insight as to whether better glucose control results in preserved function or whether preserved function allows for better A1C. Prospectively conducted trials with clinical data such as insulin use, carbohydrate consumption, and exercise may be helpful to address this question.
This article documents the frequency of preserved ␤-cell function in a population-based racially/ethnically diverse cohort of antibody-positive youth with diabetes. Although the fasting C-peptide concentration in antibody-positive youth with diabetes is often below normal, these data suggest that clinically significant amounts may persist in some individuals for some time even among subjects with more than one autoantibody. Furthermore, these data indicate that there is a marked relationship between age at diagnosis, race/ethnicity, and residual Cpeptide. Differences in pathophysiology between non-Hispanic white youth and youth of other races/ethnicities may be present. Incorporating age and race/ ethnicity into assessments of residual ␤-cell function may provide a better picture of the natural history of disease both before and after diagnosis and a more accurate assessment of the effectiveness of interventions designed to prevent ␤-cell destruction. School of Medicine (U01 DP000244); and Wake Forest University School of Medicine (U01 DP000250).
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